Hubei Guangji Pharmaceutical Co Ltd (000952) — Tangible Net Worth Ratio

Latest as of March 2026: 65.9%

Hubei Guangji Pharmaceutical Co Ltd (000952) has a Tangible Net Worth Ratio of 65.9% as of March 2026. This metric is calculated by deducting intangible assets (CN¥202.37 Million) from net assets (CN¥593.68 Million) and expressing it as a percentage of total net assets. A higher ratio means that more of the company's equity is backed by tangible, balance-sheet-verifiable assets rather than goodwill, patents, or brand value. See 000952 total equity for net asset value and shareholders' equity analysis.

Tangible NW Ratio

65.9%
Tangible equity / total equity

Net Assets (Equity)

CN¥593.68 Million
CNY

Intangible Assets

CN¥202.37 Million
Goodwill, patents, brand value

Total Assets

CN¥2.29 Billion
CNY

Hubei Guangji Pharmaceutical Co Ltd Tangible Net Worth Ratio (1996–2025)

This chart shows how Hubei Guangji Pharmaceutical Co Ltd's Tangible Net Worth Ratio has changed across 30 annual periods from 1996 to 2025. As of March 2026, the ratio stands at 65.9%, reflecting net assets of CN¥593.68 Million with intangible assets of CN¥202.37 Million CNY. Also explore net asset momentum of Hubei Guangji Pharmaceutical Co Ltd to track the company's year-over-year net asset growth rate.

Annual Tangible Net Worth Ratio for Hubei Guangji Pharmaceutical Co Ltd (1996–2025)

The table below presents the year-by-year Tangible Net Worth Ratio for Hubei Guangji Pharmaceutical Co Ltd from 1996 to 2025, covering 30 annual filings. Each row shows net assets, intangible assets, total assets, the tangible net worth ratio, and the change in percentage points versus the prior year. For the full company profile including market capitalisation, see 000952 market cap.

Year Tangible NW Ratio Net Assets (CNY) Intangible Assets Total Assets Change (pp)
2025 67.5% CN¥626.85 Million CN¥203.82 Million CN¥2.31 Billion ▼ -10.2 pp
2024 77.7% CN¥1.08 Billion CN¥239.62 Million CN¥2.79 Billion ▼ -6.7 pp
2023 84.4% CN¥1.39 Billion CN¥216.91 Million CN¥3.03 Billion ▼ -5.5 pp
2022 89.9% CN¥1.49 Billion CN¥150.62 Million CN¥2.47 Billion ▲ +0.6 pp
2021 89.3% CN¥1.45 Billion CN¥154.72 Million CN¥2.05 Billion ▲ +1.2 pp
2020 88.2% CN¥1.37 Billion CN¥161.57 Million CN¥1.98 Billion ▲ +5.6 pp
2019 82.5% CN¥964.30 Million CN¥168.48 Million CN¥1.77 Billion ▲ +1.3 pp
2018 81.2% CN¥880.96 Million CN¥165.48 Million CN¥1.69 Billion ▲ +3.3 pp
2017 77.9% CN¥765.24 Million CN¥169.33 Million CN¥1.64 Billion ▲ +5.6 pp
2016 72.2% CN¥659.18 Million CN¥183.03 Million CN¥1.63 Billion ▲ +9.6 pp
2015 62.7% CN¥513.86 Million CN¥191.78 Million CN¥1.62 Billion ▲ +1.0 pp
2014 61.7% CN¥505.45 Million CN¥193.48 Million CN¥1.58 Billion ▼ -11.5 pp
2013 73.2% CN¥735.04 Million CN¥196.89 Million CN¥1.55 Billion ▼ -1.7 pp
2012 74.9% CN¥760.05 Million CN¥190.89 Million CN¥1.56 Billion ▼ -16.4 pp
2011 91.3% CN¥863.60 Million CN¥74.97 Million CN¥1.51 Billion ▼ -1.2 pp
2010 92.5% CN¥839.35 Million CN¥62.60 Million CN¥1.38 Billion ▲ +0.5 pp
2009 92.0% CN¥816.91 Million CN¥65.03 Million CN¥1.30 Billion ▲ +2.4 pp
2008 89.7% CN¥811.28 Million CN¥83.88 Million CN¥1.21 Billion ▼ -2.4 pp
2007 92.0% CN¥673.00 Million CN¥53.68 Million CN¥998.76 Million ▲ +0.1 pp
2006 91.9% CN¥477.68 Million CN¥38.61 Million CN¥785.02 Million ▼ -0.2 pp
2005 92.1% CN¥531.76 Million CN¥41.88 Million CN¥882.44 Million ▲ +0.8 pp
2004 91.3% CN¥523.19 Million CN¥45.53 Million CN¥911.95 Million ▲ +1.0 pp
2003 90.3% CN¥514.56 Million CN¥49.84 Million CN¥866.94 Million ▲ +0.8 pp
2002 89.5% CN¥506.86 Million CN¥53.19 Million CN¥819.91 Million ▼ -0.8 pp
2001 90.3% CN¥486.87 Million CN¥47.31 Million CN¥761.83 Million ▼ -1.9 pp
2000 92.2% CN¥481.54 Million CN¥37.53 Million CN¥676.22 Million ▲ +0.4 pp
1999 91.8% CN¥449.30 Million CN¥36.64 Million CN¥648.78 Million ▲ +9.7 pp
1998 82.1% CN¥191.95 Million CN¥34.34 Million CN¥378.76 Million ▲ +4.1 pp
1997 78.1% CN¥166.21 Million CN¥36.47 Million CN¥333.05 Million ▲ +5.6 pp
1996 72.4% CN¥134.18 Million CN¥37.01 Million CN¥244.89 Million
pp = percentage points